InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1
Telomir Pharmaceuticals (NASDAQ: TELO) announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice toxicology and safety pharmacology studies for its lead therapeutic candidate Telomir-1 (Zn-Telomir), reporting no treatment-related adverse or dose-limiting toxicities across cardiovascular, respiratory, phototoxicity, and repeat-dose evaluations in both rodent and non-rodent models. The preclinical-stage biotechnology company said Telomir-1 was well tolerated with no concerning cardiac or respiratory safety signals,…